March 29, 2022 5:13pm

Earnings: Adverum Biotechnologies (ADVM)

Pre-open indications: 3 Hits and 2 MISS

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The metrics say it all … just the facts

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +338.30 points (+0.97%); the S&P closed UP +56.08 points +1.23%) while the Nasdaq closed UP +264.73 points (+1.84%)

 

Henry’omics:

Indexes rose on Tuesday...

As consumer confidence in the U.S. rose for the first time this year as a strong labor market and waning concerns over Covid-19 offset concerns over rising inflation and the war in Ukraine.

·         The conference board’s consumer confidence index came in at 107.2, below the 107.5 expected.

·         The Job Openings and Labor Turnover Survey showed 11.3 million job openings, higher than the 11.1 M expected.

Shares of Moderna (MRNA) rose 4.4% after U.S. regulators approved an additional Covid vaccine booster shot for people age 50 and over.

 

All-time low:

  • Applied Genetic Technologies (AGTC) closed at $1.12 even after an offering.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Tuesday opened positive at 32 up/2 downs, 1 flat, stayed positive at the mid-day at 32/2 and 1 flat, ending with a positive close of 32/3;
  • Monday opened negative at 28 up/5 downs, 2 flats, stayed negative at the mid-day at 6/29 and 0 flat, ending with a negative close of 13/20 and 2 flats;

 

Pre-open Indications: 3 Hits < Biostage (BSTG -$0.50), Caribou Biosciences (CRBU +$0.11), CRISP Therapeutics (CRSP +$3.12)> 2 Miss < Agenus (AGEN +$0.12), BioLife Solutions (BLFS +$1.49)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … (VSTM, BCLI & ADVM) added with 34 to date

 

Key Metrics:

  • Tuesday - Sector volume was LOW with 8 of the 32-upside having higher than the 3-month average volume with LOW volume of 3 of 3-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was up +2.82% and the XBI was up +4.28%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.73 points or -3.72% at 18.90

 

Jumping with share pricing momentum (10 of 32):

  • Alnylam Pharmaceuticals (ALNY +$5.09 after Monday’s -$2,16),
  • Fate Therapeutics (FATE +$3.94),
  • Ultragenyx (RARE +$3.52 after Monday’s -$0.90),
  • Intellia Therapeutics (NTLA +$3.15 after Monday’s+$2.43),
  • CRISPR Therapeutics (CRSP -+$3.12 after Monday’s +$0.69),
  • Beam Therapeutics (BEAM +$2.97 after Monday’s +$1.03),
  • Vericel (VCEL +$2.28 after Monday’s +$1.52),
  • Editas Medicine (EDIT +$1.68),
  • Sage Therapeutics (SAGE +$1.59 after Monday’s +$1.29),
  • BioLife Solutions (BLFS +$1.49 after Monday’s +$0.30),

Hammered in today’s market (3 of 3):

  • Voyager Therapeutics (VYGER -$0.90 after Monday’s -$0.97),
  • Biostage (BSTG -$0.50 with 3,330 shares traded after Monday’s +$0.25 with 13,012 shares traded),
  • Applied Genetic Technologies (AGTC -$0.02),

 

March, Q1/2022:

  • Tuesday closed positive with 32 incliners and 3 decliners
  • Monday closed negative with 13 incliners, 20 decliners and 2 flats

 

The BOTTOM LINE: The cell and gene therapy sector bounced as the oversold garnered attention after Monday and Friday’s losses.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought.  

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.